cefaclor capsule
carlsbad technology, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 250 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae, staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis, caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclo
cefaclor suspension
pack pharmaceuticals, llc - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 125 mg in 5 ml - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae , haemophilus influenzae , and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefac
cefaclor suspension
carlsbad technology, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 125 mg in 5 ml - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae , haemophilus influenzae , and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefac
cefaclor capsule
hikma pharmaceuticals usa inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 250 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphylococci skin and ski
cefaclor tablet, film coated, extended release
teva pharmaceuticals usa, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets usp and other antibacterial drugs, cefaclor extended-release tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have not been established. when administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the desig
cefaclor- cefaclor capsule
pd-rx pharmaceuticals, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 500 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae , haemophilus influenzae, and streptococcus pyogenes pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphy
cefaclor capsule
physicians total care, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae , and streptococcus. note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cef
cefaclor suspension
rebel distributors corp - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg in 5 ml - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae, haemophilus influenzae , and streptococcus. note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is gene
cefaclor
chanelle medical - cefaclor - capsules hard - 250 milligram - cefaclor
cefaclor
chanelle medical - cefaclor - capsules hard - 500 milligram - cefaclor